BioPharma industry leaders share their valuable thoughts for the year 2013.
I would expect 2013 to be a continuation of some of the trends we started seeing in 2012. In domestic pharma market National List of Essential Medicines (NLEM) will be a significant factor as also a focus by companies on building brands/improved sales force effectiveness. Increased co-marketing and licensing deals in the domestic market [both for prescription (Rx )and over-the-counter (OTC)]. In international generics space, there will be increased focus on value-over-volume for regulated markets and increasing relevance of emerging markets. R&D effectiveness will be crucial. Novel Drug Delivery Systems (NDDS) and niche technologies will continue to be a focus area. With increase in drug development costs, big pharma will return as clients for custom manufacturing and clinical research organizations (CRO). There will be growth in Contract Research and Manufacturing Services (CRAMS).
- Mr Ajit Mahadevan, partner, Life Sciences, Business Advisory Services, Ernst & Young
Globally, 2013 is a critical year that will indicate the impact of Euro-zone debt and the so-called US "fiscal cliff." Both these events are likely to have two significant impacts on government budgets. First, they are likely to reduce public spending on healthcare [growth of healthcare costs is higher than growth in gross domestic product (GDP) in most the Organization for Economic Co-operation and Development (OECD countries] and increase the pressure for new healthcare products to differentiate and show comparative benefits. Second, the impact on budgets could also reduce government spending on medical research (for example, budgets in premier biomedical research institutes such as the National Institutes of Health in the United States have been relatively flat); this could have a long-lasting impact on innovative biomedical research and ultimately new products and services in healthcare.
Indian healthcare, which is different from most OECD countries, is driven primarily by out-of-pocket expenses and private expenditure. In fact, India GDP growth has not been matched by growth in public healthcare spending (a paltry 1.2 percent of GDP); increases have been primarily in out-of-pocket, private spending. High out-of-pocket expenses, a primary reason that causes patients to fall into debt and poverty, are an important political issue both at the national level and in a global forum such as the United Nations. In order to ameliorate this situation, various groups are looking at universal healthcare coverage as critical to improving healthcare outcomes in India.